<DOC>
	<DOCNO>NCT00894387</DOCNO>
	<brief_summary>This study evaluate effect early initiation aliskiren therapy , compare standard therapy , reduction cardiovascular death heart failure re-hospitalization event within 6 month , congestive heart failure ( CHF ) patient hospitalize episode acute decompensated heart failure .</brief_summary>
	<brief_title>Six Months Efficacy Safety Aliskiren Therapy Top Standard Therapy , Morbidity Mortality Patients With Acute Decompensated Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion criterion : Patient hospitalize primary diagnosis worsen heart failure ≥ 18 year age , male female . Patients diagnosis acute heart failure express symptom ( dyspnea fatigability NYHA Class IIIIV ) sign fluid overload ( i.e. , jugular venous distension , edema positive rale auscultation pulmonary congestion chest xray ) time hospitalization . LVEF &lt; 40 % ( measure within last 6 month ) . Hospitalization ADHF remain `` stabilized '' least 6 hour ( define SBP ≥ 110 mm Hg acute decompensated episode ) receive IV vasodilator ( nitrate ) and/or IV inotropic drug anytime ADHF presentation time randomization . Elevated BNP Visit 1 randomization ( BNP ≥ 400 pg/ml ) . Patients history chronic heart failure standard therapy define require HF treatment least 30 day current hospitalization ( NYHA Class II IV ) . Patients require use IV vasodilator ( except nitrate ) , and/or IV inotropic therapy time presentation worsen HF randomization . Concomitant use ACEI ARB randomization . Right heart failure due pulmonary disease . Diagnosis postpartum cardiomyopathy . Myocardial infarction cardiac surgery , include percutaneous transluminal coronary angioplasty ( PTCA ) , within past 3 month . Patients history heart transplant transplant list . Unstable angina coronary artery disease likely require coronary artery bypass graft ( CABG ) PTCA randomization . Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>elevate BNP</keyword>
	<keyword>reduce LVEF</keyword>
	<keyword>Acute Heart Failure</keyword>
	<keyword>Cardiovascular death</keyword>
	<keyword>CHF</keyword>
	<keyword>hospitalization</keyword>
	<keyword>morbi-mortality trial</keyword>
	<keyword>outcome study</keyword>
	<keyword>endpoint driven</keyword>
	<keyword>plasma renin activity</keyword>
	<keyword>renin angiotensin</keyword>
	<keyword>aldosterone system</keyword>
	<keyword>direct renin inhibitor</keyword>
	<keyword>BNP</keyword>
	<keyword>KCCQ</keyword>
	<keyword>eGFR</keyword>
</DOC>